FGH BioTech Overview
- Year Founded
-
2011
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.08M
- Investors
-
2
FGH BioTech General Information
Description
Developer of small-molecule drugs designed to treat metabolic disorders and cancer. The company's drugs target the master regulatory switch for fat production, known as sterol regulatory element-binding proteins, enabling physicians to treat obesity, non-alcoholic fatty liver disease, type II diabetes, and lipid disorders.
Contact Information
Website
www.fghbiotech.comCorporate Office
- 414 Thamer Circle
- Houston, TX 77024
- United States
Corporate Office
- 414 Thamer Circle
- Houston, TX 77024
- United States
FGH BioTech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 19-May-2018 | $2.08M | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series A) | 18-Mar-2016 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 06-Nov-2015 | Cancelled | Generating Revenue | |||
| 1. Grant | 01-Jan-2014 | $1.84M | Completed | Generating Revenue |
FGH BioTech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
FGH BioTech Patents
FGH BioTech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020132700-A1 | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof | Inactive | 21-Dec-2018 | ||
| AU-2017323521-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Active | 07-Sep-2016 | ||
| AU-2017323521-B2 | Di-substituted pyrazole compounds for the treatment of diseases | Active | 07-Sep-2016 | ||
| AU-2017323521-B9 | Di-substituted pyrazole compounds for the treatment of diseases | Active | 07-Sep-2016 | ||
| CA-3036195-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Active | 07-Sep-2016 | C07D401/14 |
FGH BioTech Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BCM Ventures | Venture Capital | Minority | ||
| U.S. Department of Health and Human Services | Government |
FGH BioTech FAQs
-
When was FGH BioTech founded?
FGH BioTech was founded in 2011.
-
Where is FGH BioTech headquartered?
FGH BioTech is headquartered in Houston, TX.
-
What industry is FGH BioTech in?
FGH BioTech’s primary industry is Drug Discovery.
-
Is FGH BioTech a private or public company?
FGH BioTech is a Private company.
-
What is FGH BioTech’s current revenue?
The current revenue for FGH BioTech is .
-
How much funding has FGH BioTech raised over time?
FGH BioTech has raised $7.08M.
-
Who are FGH BioTech’s investors?
BCM Ventures and U.S. Department of Health and Human Services have invested in FGH BioTech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process